These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24076578)

  • 1. Immunotherapeutics for breast cancer.
    Criscitiello C; Curigliano G
    Curr Opin Oncol; 2013 Nov; 25(6):602-8. PubMed ID: 24076578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunizing against breast cancer: a new swing for an old sword.
    Curigliano G; Locatelli M; Fumagalli L; Goldhirsch A
    Breast; 2009 Oct; 18 Suppl 3():S51-4. PubMed ID: 19914543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunology and breast cancer: therapeutic cancer vaccines.
    Curigliano G; Rescigno M; Goldhirsch A
    Breast; 2007 Dec; 16 Suppl 2():S20-6. PubMed ID: 17706425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapeutic options on the horizon in breast cancer treatment.
    van Rooijen JM; Stutvoet TS; Schröder CP; de Vries EG
    Pharmacol Ther; 2015 Dec; 156():90-101. PubMed ID: 26388292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards a therapeutic breast cancer vaccine: the next steps.
    Emens LA
    Expert Rev Vaccines; 2005 Dec; 4(6):831-41. PubMed ID: 16372879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The anti-tumor immune response in breast cancer: Update and therapeutic perspectives].
    Ladoire S; Derangère V; Arnould L; Thibaudin M; Coudert B; Lorgis V; Desmoulins I; Chaix M; Fumoleau P; Ghiringhelli F
    Ann Pathol; 2017 Feb; 37(1):133-141. PubMed ID: 28159406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.
    Emens LA
    Expert Rev Anticancer Ther; 2012 Dec; 12(12):1597-611. PubMed ID: 23253225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of breast cancer.
    Wright SE
    Expert Opin Biol Ther; 2012 Apr; 12(4):479-90. PubMed ID: 22413825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antitumor immunity and cellular cancer therapies].
    Catros-Quemener V; Bouet F; Genetet N
    Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
    Ramsay AG
    Br J Haematol; 2013 Aug; 162(3):313-25. PubMed ID: 23691926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
    Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
    Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the immune system to treat lung cancer: rationale and clinical experience.
    Guibert N; Delaunay M; Mazières J
    Ther Adv Respir Dis; 2015 Jun; 9(3):105-20. PubMed ID: 25827132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor immunity and advances in cancer immunotherapy.
    Sugie T; Toi M
    Breast Cancer; 2017 Jan; 24(1):1-2. PubMed ID: 27882505
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
    Huang Y; Shah S; Qiao L
    Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immune-checkpoints: the new anti-cancer immunotherapies].
    Ileana E; Champiat S; Soria JC
    Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint modulation: rational design of combination strategies.
    Zamarin D; Postow MA
    Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of novel immunotherapy targeting cancer immune evasion].
    Tamada K
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1062-5. PubMed ID: 25248888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
    Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
    Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.